Valeant/GSK's Anti-Epileptic Potiga Faces Advisory Committee In Mid-August
This article was originally published in The Pink Sheet Daily
Executive Summary
High rate of adverse event-related dropouts in clinical trials could be a key focus of panel's discussion of ezogabine, also known as retigabine.